📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial. (2021)

First Author: Frater J

Attributed to: Natural Killer Cells as Effectors in HIV Cure Strategies funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/s2352-3018(21)00103-x

PubMed Identifier: 34153264

Publication URI: http://europepmc.org/abstract/MED/34153264

Type: Journal Article/Review

Volume: 8

Parent Publication: The lancet. HIV

Issue: 8

ISSN: 2352-3018